PCSK9 inhibitors work – but access is the problem
Prof Chris Packard (University of Glasgow, UK)
The take home message from this US study: A high absolute risk reduction (in high-risk patients with high LDL-C) is paramount to the cost effectiveness of PCSK9 inhibitors.
Read the Report
Recent Hot Topics:
Prof Børge Nordestgaard: Lipoprotein(a): a therapeutic target in guidelines?
Listen to the presentation
Prof Raul Santos: Coronary artery calcium in familial hypercholesterolaemia Read the Report